Yesterday, Two Pore Guys (2PG), which develops handheld nanodiagnostic technology, announced that it has received $24.5 million in Series A funding, led by Khosla Ventures.
The new funding will be used to expand the manufacturing of its handheld test systems, expand the company's executive team, and further develop its nanopore technology for genome-wide sequencing and genome mapping.
Founded in 2011, the company is headquartered in Santa Cruz, Calif., and received $5.11 million in financing in 2016. The handheld single-molecule sensing platform developed by 2PG almost “hands-on†medical laboratory equipment to monitor blood glucose, viruses, bacteria and antibodies.
Company technology introduction
Two Pore Guys (2PG) uses solid-state nanopore technology for digital and single-molecule sensing. Nanopore technology accurately detects each molecule by measuring the change in current of each molecule passing through the nanopore. Devices transfer data to authorized systems and cloud infrastructure for telemedicine , drug discovery, clinical trials, and global tracking of disease.
Its hand-held single-molecule sensing platform has the same accuracy, precision and sensitivity as medical laboratory equipment, and has sampling and reading functions. This sensing platform uses a one-time test strip to accurately detect "almost any molecule" as a medical laboratory. Its core technology is a solid-state nanopore sensor that detects nucleic acids and proteins and other components in human, animal, agricultural and environmental samples.
2PG's business model is a bit like a smartphone app store. Specific tests are developed by third parties to detect almost all kinds of molecules. Even the traditional centralized laboratory equipment is now suitable for 2PG platforms. A powerful aspect of this platform is that it allows for an unrestricted increase in high-sensitivity test items on the menu, which is very good at meeting market demands. The company's main products are its reading equipment and test strips, as well as testing reagents that work with other companies, sold through the main distributor.
Currently, the company has begun to form cooperation in multiple areas, and the next step is to test the platform, which is similar to the software developer testing smartphone application. Target areas for new technologies include medical diagnostics for humans and animals, agriculture, food safety testing, environmental monitoring, and defense.
Food Ingredient Fructo-Oligosaccharide,Organic Oligofructose GOS,Digestion Resistant Fiber
Qingdao Bailong Huichuang Bio-tech Co., Ltd. , https://www.qdblcycn.com